Vivani Medical, Inc. Common Stock (DE) (VANI) is a publicly traded Healthcare sector company. As of May 21, 2026, VANI trades at $1.19 with a market cap of $98.31M and a P/E ratio of -2.73. VANI moved +3.48% today. Year to date, VANI is -5.56%; over the trailing twelve months it is +3.48%. Its 52-week range spans $0.91 to $1.92. Analyst consensus is buy with an average price target of $3.75. Rallies surfaces VANI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vivani Medical Secures $28M Cash Runway as SLIM-1 Trial Kicks Off Mid-2026: Vivani Medical ended Q1 with a $6.8M net loss, $6.2M operating cash burn and $28M in cash, cash equivalents and commitments funding operations through H1 2027. The company plans to initiate its SLIM-1 Phase 1 semaglutide implant study mid-2026 with topline results by year-end.
| Metric | Value |
|---|---|
| Price | $1.19 |
| Market Cap | $98.31M |
| P/E Ratio | -2.73 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.92 |
| 52-Week Low | $0.91 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.61M |
| Gross Margin | 0.00% |
2 analysts cover VANI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.75.